Some of the studies described in the review based on animal models so far have shown beneficial effects in reducing asthma symptoms by activating nociception NOP1, bombesin BRS-3 and somatostatin SST4 receptors, or blocking the NPY-Y1 receptor. This evidence concerns the gene BRS3 and asthma.